CHRONIC GINGIVOSTOMATITIS TREATMENT MARKET ANALYSIS

Chronic Gingivostomatitis Treatment Market, by Diagnosis (Physical Examination, Microbial Culture, Biopsy, and Others), by Treatment (Non-steroidal Anti-inflammatory Drugs, Antiviral, Antibacterial, and Others), by End User (Hospitals & Clinics, Academic & Research, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Dec 2020
Code : CMI4308
Pages :180
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Misidentification or diagnosis of chronic gingivostomatitis

Global Chronic Gingivostomatitis Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector, which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has caused an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products, and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global chronic gingivostomatitis treatment market during the forecast period.

Increasing incidence of chronic gingivostomatitis in North America is expected to boost the market growth

North America is expected to hold dominant position in the global chronic gingivostomatitis treatment market, owing to increasing new cases of chronic gingivostomatitis in the region. For instance, according to the Western Journal of Emergency Medicine, an article - Cost of Routine Herpes Simplex Virus Infection Visits to U.S. ED 2006-2013, published in 2018, reports that there were 115,726 number of patient visits with primary diagnosis during 2006-2013 in the U.S.